Seibel M J
Abteilung Innere Medizin I, Universitätsklinik Heidelberg.
Ther Umsch. 1998 Nov;55(11):676-84.
Over the past years, the development of new biochemical markers of bone metabolism has generated a substantial amount of data about the pathogenesis, diagnosis, prevention and treatment of osteoporotic bone disease. When used in combination with clinical data and imaging techniques, these parameters permit a comprehensive and non-invasive evaluation of the skeletal status. Biochemical markers of bone metabolism may therefore be used to predict future bone loss and hip fractures in larger cohorts, to select therapy for individual patients, to predict the therapeutic response in individual patients, to monitor therapeutic response and efficacy in, and compliance of individual patients. As far as the initial clinical diagnosis of osteoporosis is concerned, none of the biochemical markers of bone turnover has proven useful as a single determination. Nevertheless, once the diagnosis of osteoporotic bone disease is made, biochemical markers of bone metabolism are useful tools in the further work-up, particularly in identifying patients with high rates of bone turnover. Furthermore, patients with high bone turnover appear to profit from anti-resorptive treatments more than subjects with low or normal bone metabolism. The measurement of bone turnover may therefore not only be useful in therapeutic decision making but can also help to reduce costs by identifying those individuals who may not respond well to treatment. Finally, bone markers are of clinical relevance in monitoring both the disease itself and therapeutic efficacy.
在过去几年中,骨代谢新生物标志物的发展产生了大量有关骨质疏松性骨病发病机制、诊断、预防和治疗的数据。当与临床数据和成像技术结合使用时,这些参数可对骨骼状况进行全面且非侵入性的评估。因此,骨代谢生物标志物可用于预测更大队列中的未来骨质流失和髋部骨折,为个体患者选择治疗方法,预测个体患者的治疗反应,监测个体患者的治疗反应和疗效以及依从性。就骨质疏松症的初步临床诊断而言,尚无任何骨转换生物标志物被证明可作为单一测定方法有用。然而,一旦做出骨质疏松性骨病的诊断,骨代谢生物标志物就是进一步检查中的有用工具,特别是在识别骨转换率高的患者方面。此外,骨转换率高的患者似乎比骨代谢低或正常的患者从抗吸收治疗中获益更多。因此,骨转换的测量不仅在治疗决策中有用,还可以通过识别那些可能对治疗反应不佳的个体来帮助降低成本。最后,骨标志物在监测疾病本身和治疗效果方面具有临床相关性。